SAN JUAN CAPISTRANO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of Ashley River Healthcare, a 125-bed skilled nursing facility located in Charleston, South Carolina, and The Reserve Healthcare and Rehabilitation, a 135-bed skilled nursing facility located in Hanahan, South Carolina. These acquisitions were effective September 1, 2023 and will be subject to a long-term, triple net lease.
“We are very excited for our continued growth in South Carolina,” said Barry Port, Ensign's Chief Executive Officer. “These buildings present a great geographical and strategic fit within this particular market,” he added.
Adam Willits, President of Hopewell Healthcare LLC, Ensign’s South Carolina-based subsidiary, added “We can’t wait to work with the wonderful caregivers at each of these facilities as we seek to meet and exceed the clinical, emotional and social needs of the residents and families we are honored to serve.”
These acquisitions bring Ensign's growing portfolio to 295 healthcare operations, 26 of which also include senior living operations, across thirteen states. Ensign subsidiaries, including Standard Bearer, now own 112 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.
About Ensign™
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 295 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.
Contact Information
The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$134.59 |
Daily Change: | -0.53 -0.39 |
Daily Volume: | 833,968 |
Market Cap: | US$7.710B |
December 18, 2024 November 13, 2024 November 04, 2024 October 29, 2024 October 24, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB